Abstract

Background
The indications for lumbar puncture in non-HIV-infected, non-transplant (NHNT) patients with cryptococcosis without meningeal signs need to be more fully defined.

Objectives
This study was designed to determine the optimal predictors of central nervous system (CNS) involvement in adult NHNT patients with cryptococcosis.

Methods
The study population consisted of adult NHNT patients with culture-confirmed cryptococcosis who sought care at a university hospital in Taiwan from 2002 to 2016. We used a case-control method to identify the clinical characteristics and laboratory findings associated with CNS involvement in patients who underwent a diagnostic lumbar puncture. In the sensitivity analysis, we included additional control patients who did not undergo lumbar puncture, but were followed beyond 12 months without the development of CNS involvement in the absence of exposure to any fungicidal agents.

Results
We entered 270 NHNT adult patients into the study during the 15-year period. CNS involvement was confirmed in 66 (71.0%) of 93 patients who underwent lumbar puncture. A multivariable analysis revealed that presence of neurological manifestations and elevated serum CRAG titers were independently associated with a 23.97-fold (95% confidence interval [CI], 4.37–182.23) and 1.53-fold (per 2-fold increment, 95% CI 1.26–1.92) increased odds ratio for CNS involvement, respectively. Headache and focal neurologic signs were
independently associated with CNS involvement. A cut-off serum CRAG titer of $\geq 1:64$ provided the highest diagnostic performance by Youden index (sensitivity 83% and specificity 65%). Similar findings were noted in the sensitivity analysis including 198 (73%) patients.

**Conclusion**

Lumbar puncture is indicated for NHNT patients with cryptococcosis who have neurologic manifestations or a serum CRAG titer of $\geq 1:64$.

**Introduction**

Central nervous system (CNS) involvement is the most serious complication of cryptococcosis because of its high mortality and debilitating neurologic sequelae among the survivors [1,2]. Treatment of CNS cryptococcosis requires a combination of fungicidal agents during the induction phase and aggressive control of intracranial pressure to improve early survival [2–4].

Many of the recent advances in the management of patients with cryptococcosis have been generated from studies of patients with HIV infection and organ transplant recipients [5]. Non-HIV-infected, non-transplant (NHNT) patients account for a substantial proportion of patients with cryptococcosis [6–9]. Their optimal management is less well defined.

NHNT patients with cryptococcosis are reported to have a lower rate of CNS involvement than HIV-infected patients or organ transplant recipients [6,9]. Nevertheless, they had a higher mortality rate [6–9] and severe neurologic morbidities [10,11] when CNS involvement became evident. The time from presenting symptoms to confirmed diagnosis is also longer in NHNT patients than HIV-infected patients or organ transplant recipients. Several reports have linked this to poorer outcomes [6,9,12].

Cerebrospinal fluid (CSF) analysis is required to confirm or exclude CNS involvement in patients with cryptococcosis. Imaging studies are neither sensitive nor specific [2,3,5]. Routine lumbar puncture is recommended for patients with HIV infection, other severe immunocompromising conditions, and disseminated cryptococcosis with clinical presentations compatible with CNS infection [3,5]. However, there is limited evidence to support this recommendation for NHNT patients with cryptococcosis and compliance to guidelines is reported to be suboptimal [13]. This study was designed to determine the clinical and laboratory predictors of CNS involvement in NHNT patients in order to identify those who would more likely benefit from a lumbar puncture.

**Patients and methods**

**Study design and patients**

This case-control study was conducted at the National Taiwan University Hospital, a 2,300-bed teaching hospital located in northern Taiwan that provides both primary and tertiary healthcare. We reviewed the records of patients with one or more positive cultures for *Cryptococcus neoformans/Cryptococcus gattii* species complex isolated from any clinical specimens from 2002 to 2016. A standard case recording form was used to collect data on demographic characteristics, predisposing factors, clinical presentations, and laboratory investigations.
Routine care for patients with cryptococcal disease in this hospital during the past 2 decades includes provider-initiated testing and counseling for HIV, determination of serum cryptococcal antigen, and lumbar punctures in accordance with current guidelines [3,5]. The details for management in patients with cryptococcal meningitis [14] and cryptococcemia [15], and control of intracranial pressure [16] have been described in the third version of the Taiwan national guidelines published in 2016 [17]. The study was approved by the Research Ethical Committee of the National Taiwan University Hospital with a waiver of informed consent (register number 201802002RIND). The study was carried out in accordance with the approved ethical guidelines and regulations.

Definitions
Culture-confirmed cryptococcal disease was defined as either a positive culture for \textit{C. neoformans}/\textit{C. gattii} species complex obtained from a sterile site or a positive culture from a non-sterile site plus a compatible clinical presentation. We excluded patients with an incidental positive culture of \textit{C. neoformans} from a non-sterile site, who did not have cryptococcosis-relevant signs and symptoms, and had not received antifungal treatment at this hospital.

The primary study population consisted of hospitalized adult NHNT patients with both culture-confirmed cryptococcal disease and CSF data. They were divided into two groups according to the findings of their CSF analyses. Cases consisted of patients with cryptococcosis and CNS involvement. CNS involvement was defined as the presence of either a positive CSF culture for \textit{C. neoformans} or a positive CSF CRAG titer \(\geq 1:8\). Controls consisted of patients with cryptococcosis without CNS involvement.

For the sensitivity analysis we added patients with cryptococcosis, who did not have a lumbar puncture, to the primary study group because CNS involvement was deemed very unlikely. These patients were treated with azoles or observed without antifungal therapy. None were treated with amphotericin B or flucytosine. They were followed for more than 12 months without development of CNS disease or recurrence of cryptococcosis.

Chronic liver disease was defined as either the presence of serologic markers for chronic hepatitis B or C, or clinical and radiologic findings suggestive of cirrhosis of the liver. Chronic kidney disease was defined as persistence of markers of renal damage such as proteinuria or an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m\(^2\) for at least 3 months. Prolonged steroid exposure was defined as a mean minimum dose of 0.3 mg/kg/day of prednisolone for \(>3\) weeks according to EORTC/MSG consensus [18]. Selected medical conditions recorded in this study included diabetes mellitus, chronic liver and kidney diseases, autoimmune diseases, hematologic or solid-organ malignancies, use of steroids or other immunosuppressant agents, and hypogammaglobulinemia. Neurologic manifestations included headaches, altered mental status, seizures, meningeal signs and focal neurologic signs. Neutropenia and lymphocytopenia were defined as an absolute neutrophil and lymphocyte count of less than 1,500 and 1,000 cells/\(\mu\)L, respectively. Hyponatremia was defined as a serum sodium level of less than 136 mmol/L.

Laboratory investigations
Cryptococci were identified by standard mycological techniques for \textit{C. neoformans}/\textit{C. gattii} species complex as previously described [19]. A previous island-wide surveillance study has shown that \textit{C. gattii} accounted for only 4.1\% of the clinical cryptococcal isolates [7]. We did not differentiate \textit{C. neoformans} from \textit{C. gattii} in the present study. Serum cryptococcal antigen (CRAG) assays were performed using the Latex-Cryptococcus Antigen Test (IMMY, Oklahoma, USA) according to the manufacturer’s instructions.
Statistical analyses

Statistical analyses were performed using R statistics software (Version 3.3.3, the R Foundation). Continuous variables were compared by Student’s t-test or Mann-Whitney U tests. Categorical variables were compared by Fisher’s exact test between the groups with and without CNS involvement. Titers of serum CRAG were log$_2$-transformed before analyses. Variables with a $p$-value <0.2 in univariable analyses were entered into a binary logistic regression model for multivariable analysis, where missing values (including 1 serum sodium level and 8 serum CRAG titers) were treated by imputation with means. All tests were two-tailed. A $p$-value of <0.05 was considered significant. The same process of analyses was repeated in the sensitivity analysis.

Post hoc analyses of the primary study population were performed to elucidate the correlation between the identified variables and CNS involvement. This included a multivariable analysis of various neurologic manifestations to identify the most relevant neurologic signs and symptoms, a receiver operating characteristic (ROC) curve to demonstrate the diagnostic performance of serum CRAG titers to predict CNS involvement, and calculation of Youden indices [20] to determine the optimal serum CRAG cut-off values.

Results

During the 15-year study period, we identified 361 adult patients with culture-confirmed cryptococcal diseases (Fig 1). Most, 270 (74.8%), were NHNT. After appropriate exclusion, shown in Fig 1, 93 of the NHNT patients that had a lumbar puncture were entered into the primary study population. A total of 198 NTHT patients were entered into the sensitivity analysis (66 with CNS involvement and 132 without CNS involvement).

Characteristics of the primary study population

Ninety-three patients were enrolled in the primary study population. Almost two-thirds were male. The median age was 61 years (interquartile range (IQR) 51–70). Most of the patients (80.6%) had at least one underlying immunocompromising medical condition. The most common conditions were exposure to steroids or other immunosuppressants, diabetes mellitus, malignancies, chronic liver or kidney disease, and autoimmune diseases (Table 1). The clinical characteristics and mortality among the NHNT patients according to whether or not they had a lumbar puncture are shown in S1 Table.

Case-control analysis

In univariable analysis, patients with CNS involvement were more likely to present with neurologic manifestations (95.5% vs 59.3%, $p<0.001$), a higher median serum CRAG titer ($\geq 1:1024$ vs $1:32$, $p<0.001$) and a higher proportion of serum CRAG titers of $\geq 1:64$ (83.1% vs 34.6%, $p<0.001$). There was no significant difference between the two groups in the frequency of cryptococcemia (37.9% vs 29.6%, $p = 0.485$) or a positive culture from extrapulmonary, extracranial sites (13.6% vs 29.6%, $p = 0.083$).

Variables including neurological manifestations, serum CRAG titers, lymphocytopenia, hyponatremia, and involvement of extrapulmonary, extracranial sites were entered into the multivariable model. The presence of neurologic manifestations and higher serum CRAG titers were found to be independently associated with CNS involvement with an odds ratio of 23.97 (95% confidence interval [CI], 4.37–182.23) and 1.53 per 1-log$_2$ serum CRAG titer increment (95% CI 1.26–1.92), respectively (Table 1). The findings were similar in the sensitivity analysis (S2 Table).
Post-hoc analysis

We further explored the associations between CNS involvement and various neurological manifestations. Patients with CNS involvement were more likely to present with headache (54.5%), meningeal signs (21.2%) and focal neurologic signs (39.4%). In multivariable analysis, headaches and focal neurologic signs were independently associated with CNS involvement (odds ratio 12.30 [95% CI 3.09–83.55] and 4.02 [95% CI 1.23–16.01], respectively) (S3 Table). Of note, 3 of 14 patients (21.4%), who had no neurologic manifestations, had CNS involvement.

The diagnostic performance of serum CRAG titers for CNS involvement, analyzed by the ROC curve method, revealed that serum CRAG titers had a good discriminative value in predicting CNS involvement. The area-under-the-curve (AUC) was 0.788 (95% C.I. 0.682–0.896) (Fig 2A). A serum CRAG titer of $\geq 1:64$ provided the highest Youden index with a sensitivity of 83% and a specificity of 65% (Fig 2B). Further analysis showed that patients with serum CRAG titers of $\geq 1:64$, compared with those with serum CRAG titers of $<1:64$, were more likely to have the presence of cryptococcemia (44.8% vs 14.8%, $p = 0.008$), lymphocytopenia (58.6% vs 33.3%, $p = 0.037$) and autoimmune diseases (34.5% vs 11.1%, $p = 0.035$), but not other immunocompromising conditions.
The effect of combinations of serum CRAG \( \geq 1:64 \) or \(< 1:64\) with or without neurological manifestations on the proportion of CNS involvement is shown in Fig 3. The highest proportion (92%, 46/50) was noted with the combination of serum CRAG \( \geq 1:64 \) and neurological manifestations. Patients with neither of these findings did not have CNS involvement in either the primary or sensitivity study populations.

### Table 1. Baseline characteristics of 93 non-HIV-infected, non-transplant patients with cryptococcosis according to CNS involvement.

|                          | All (N = 93) | With CNS involvement (N = 66) | Without CNS involvement (N = 27) | Univariate analysis | Multivariate analysis a |
|--------------------------|-------------|-------------------------------|----------------------------------|--------------------|------------------------|
|                          |             |                               |                                  | Odds ratio, 95% CI  | p-value                |
| Age, median (IQR), years | 64 (49, 72) | 65 (53, 75)                   | 62 (47, 69)                      | 1.02 (0.99, 1.05)  | 0.216                  |
| Male, n (%)              | 59 (63.4)   | 39 (59.1)                     | 20 (74.1)                        | 0.51 (0.16, 1.48)  | 0.237                  |
| Underlying medical condition(s) b, n (%) |             |                               |                                  |                    |                        |
| Steroid exposure, any    | 36 (38.7)   | 26 (39.4)                     | 10 (37.0)                        | 1.10 (0.40, 3.15)  | >0.999                 |
| Steroid exposure, prolonged c | 23 (24.7)   | 18 (24.2)                     | 7 (25.9)                         | 0.92 (0.30, 3.04)  | >0.999                 |
| Diabetes mellitus        | 28 (30.1)   | 17 (25.8)                     | 11 (40.7)                        | 0.51 (0.18, 1.47)  | 0.213                  |
| Use of immunosuppressants other than steroids d | 24 (25.8)   | 19 (28.8)                     | 5 (18.5)                         | 1.77 (0.54, 6.86)  | 0.435                  |
| Autoimmune disease       | 23 (24.7)   | 17 (25.8)                     | 6 (22.2)                         | 1.21 (0.38, 4.29)  | 0.797                  |
| Chronic liver disease e | 22 (23.7)   | 18 (27.3)                     | 4 (14.8)                         | 2.14 (0.61, 9.69)  | 0.284                  |
| Chronic kidney disease f | 19 (20.4)   | 14 (21.2)                     | 5 (18.5)                         | 1.18 (0.35, 4.72)  | >0.999                 |
| Solid organ malignancy   | 18 (19.4)   | 11 (16.7)                     | 7 (25.9)                         | 0.58 (0.17, 2.01)  | 0.387                  |
| Hematologic malignancy   | 10 (10.8)   | 8 (12.1)                      | 2 (7.4)                          | 1.72 (0.31, 17.71) | 0.718                  |
| Absence of immunocompromising conditions g | 18 (19.4)   | 12 (18.2)                     | 6 (22.2)                         | 0.78 (0.23, 2.87)  | 0.773                  |
| Symptoms and signs, n (%) |             |                               |                                  |                    |                        |
| Fever                    | 61 (65.6)   | 45 (68.2)                     | 16 (59.3)                        | 1.47 (0.52, 4.02)  | 0.474                  |
| Any neurologic manifestations h | 79 (84.9)   | 63 (95.5)                     | 16 (59.3)                        | 13.89 (3.19, 86.62)< 0.001 | 23.97 (4.37, 182.23)< 0.001 |
| Laboratory investigations |             |                               |                                  |                    |                        |
| WBC, k/\(\mu L\), median (IQR) | 7.80 (5.93, 9.98) | 7.76 (5.22, 10.42) | 7.80 (6.45, 9.68) | 1.00 (0.94, 1.08) | 0.732                  |
| Neutropenia, n (%)       | 4 (4.3)     | 2 (3.0)                       | 2 (7.4)                          | 0.40 (0.03, 5.73)  | 0.577                  |
| Lymphocytopenia, n (%)   | 47 (50.5)   | 37 (56.1)                     | 10 (37.0)                        | 2.15 (0.79, 6.12)  | 0.114                  |
| Hyponatremia, n (%) (N = 92) | 48 (52.1)   | 38 (57.6)                     | 10 (38.5)                        | 2.15 (0.78, 6.18)  | 0.111                  |
| Cryptococccemia, n (%)   | 33 (35.5)   | 25 (37.9)                     | 8 (29.6)                         | 1.44 (0.51, 4.40)  | 0.485                  |
| Positive culture(s) from extrapulmonary, extracranial sites, n (%) | 17 (18.3)   | 9 (13.6)                      | 8 (29.6)                         | 0.38 (0.11, 1.30)  | 0.083                  |
| SCRAG titer, median (IQR) (N = 85) | 512 (32, 1024) | \(\geq\)1024 (64, \(\geq\)1024) | 32 (4, 128)                     | 1.41 (1.20, 1.69)< 0.001 | 1.53 (1.26, 1.92)< 0.001 |
| SCRAG \(\geq\) 1:64, n (%) | 58 (62.8)   | 49 (83.1)                     | 9 (34.6)                         | 8.94 (2.87, 30.51)< 0.001 | 1.53 (1.26, 1.92)< 0.001 |

a Medical conditions are presented for 5 or more patients with this condition.

b Prolonged steroid exposure was defined as a minimum dose of 0.3 mg/kg/day of prednisolone for more than 3 weeks according to EORTC/MSG consensus, 2008.

c Recorded immunosuppressants other than steroid included azathioprine, bleomycin, chlorambucil, cisplatin, cyclophosphamide, doxorubicin, fluorouracil, ifosfamide, oxaliplatin, mercaptopurine, methotrexate, mycophenolic acid (MMF), vincristine.

d Chronic liver disease was defined based on evidence of chronic viral hepatitis or the presence of cirrhosis.

e Chronic kidney disease was defined when the estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m² for at least 3 months.

f Immunocompromising conditions indicated here included diabetes, chronic kidney diseases, cirrhosis of liver, autoimmune diseases, malignant diseases, use of steroid or other immunosuppressants, and hypogammaglobulinemia.

g Neurologic manifestations included headaches, altered mental status, seizures, meningeal signs and focal neurologic signs.

h Variables with p-value < 0.2 in univariate analysis were included in the multivariate analysis.

i Odds ratio per 2-fold increment of sCRAG.

Abbreviations: CI, confidence interval; CNS, central nervous system; sCARG, serum cryptococcal antigen; WBC, white blood-cell count.

https://doi.org/10.1371/journal.pone.0221657.t001
Discussion

This large, retrospective study, conducted a teaching hospital in Taiwan, was designed to determine the optimal indicators for lumbar puncture in non-HIV non-transplant patients (NHNT) with cryptococcosis. NHNT accounted for almost three quarters of patients with confirmed cryptococcal diseases at the hospital. Most patients (80.6%) had an underlying immunocompromising medical condition. We found that the presence of neurologic manifestations and elevated serum CRAG titers was independently associated with CNS involvement. A serum CRAG titer \( \geq 1:64 \) provided the highest diagnostic value. Lower titers, despite their higher sensitivity and low specificity, should not be dismissed in the presence of neurologic manifestations. Characteristic signs of meningeal inflammation were observed in only 21.2%.

Fig 2. Diagnostic performance of serum cryptococcal antigen (sCRAG) titers to predict CNS involvement in non-HIV-infected, non-transplant patients with cryptococcosis. Panel (A) shows the receiver operating characteristic (ROC) curve, area-under-the-curve (AUC) value of 0.788 (95% confidence interval 0.682 and 0.896). Panel (B) shows the sensitivities, specificities and Youden indices of sCRAG at different cut-off values.

https://doi.org/10.1371/journal.pone.0221657.g002
of our patients with CNS cryptococcosis. Similar findings have been reported previously [15,21]. Thus, a substantial number of patients would have been missed if lumbar punctures were deferred based solely on the lack of meningeal signs [14].

A strong correlation between the CSF CRAG titers and CSF cryptococcal colony-forming units has been reported [22]. Serum CRAG titers have also been shown to be associated with extrapulmonary involvement in patients with pulmonary cryptococcosis [21,23]. Serum CRAG titers may reflect the magnitude of the fungal burden. Serum CRAG titers have also been shown to be useful to predict CNS involvement in HIV-infected patients and transplant recipients [23,24]. The serum CRAG assay may be unreliable occasionally. False-positive results may be caused by the prozone phenomenon. Infection with rare species of Cryptococcus or those with thin capsules may also result in falsely low or negative CRAG assays despite positive blood or CSF cultures [25,26].

Based on the findings of the current and similar studies in patients with HIV infection and transplantation, we developed an algorithm to facilitate decision-making to perform a lumbar puncture for cryptococcosis.

![Figure 3: Proportion of patients with central nervous system involvement according to the presence or absence of neurologic manifestations and serum cryptococcal antigen (CRAG) titers of < 1:64 and ≥ 1:64. Panel (A) included 85 patients from the primary study population and had both serum CRAG tests and neurological assessment. Panel (B) included 158 patients from the sensitivity analysis population who had both serum CRAG tests and neurological assessment.](https://doi.org/10.1371/journal.pone.0221657.g003)
puncture in NHNT patients with newly diagnosed cryptococcosis (Fig 4). The presence of any neurologic manifestation or serum CRAG titers of $\geq 1:64$ should prompt performance of a lumbar puncture to detect potential CNS involvement. The procedure may be deferred with careful observations in patients without neurologic manifestations and serum CRAG titers of $<1:64$.

The strengths of this study are the large number of patients entered over a 15-year period at a large, referral teaching hospital with an electronic medical records system. The sensitivity analysis included a large number of patients who did not undergo a lumbar puncture. This provided further support for the findings of the case-control study of patients that had a lumbar puncture. The weaknesses of this study are similar to those inherent in all retrospective studies that may lose or misdiagnose some patients for a variety of reasons. NHNT patients with cryptococcosis are a heterogeneous group with a wide variety of underlying immunocompromising conditions. Recent studies have shown that novel acquired immunodeficiencies, such as idiopathic CD4 lymphocytopenia [27] and anti-granulocyte macrophage colony-stimulating factor (anti-GM-CSF) [28], are strongly associated with cryptococcosis. We did not evaluate the influence of these diseases.

In conclusion, we found that neurological manifestations or serum CRAG titers of $\geq 1:64$, alone or in combination, are strong predictors of CNS involvement in NHNT patients with cryptococcosis and are indications for a lumbar puncture. In the absence of these findings lumbar puncture could be deferred provided that the patients continue to be monitored for meningeal signs and serum CRAG as indicated by their course.

**Supporting information**

S1 Table. Baseline characteristics of 270 non-HIV-infected, non-transplant patients with cryptococcosis.

(DOCX)
S2 Table. Baseline characteristics of 198 non-HIV-infected, non-transplant patients with cryptococcosis by CNS involvement and the comparison between those with and without CNS involvement by univariable and multivariable analyses.

S3 Table. Association of various neurologic manifestations and CNS involvement among non-HIV-infected, non-transplant patients with cryptococcosis by univariable and multivariable analyses.

Acknowledgments
The authors would like to thank Professor Calvin M. Kunin for his critical review and assistance in English editing of the manuscript.

Author Contributions
Conceptualization: Sung-Hsi Huang, Hsin-Yun Sun, Yee-Chun Chen.

Data curation: Sung-Hsi Huang, Yu-Chung Chuang, Yi-Chien Lee, Yee-Chun Chen.

Formal analysis: Sung-Hsi Huang, Yu-Chung Chuang.

Funding acquisition: Yee-Chun Chen.

Investigation: Sung-Hsi Huang.

Methodology: Sung-Hsi Huang, Chien-Ching Hung, Hsin-Yun Sun, Yee-Chun Chen.

Project administration: Hsin-Yun Sun, Yee-Chun Chen.

Resources: Yee-Chun Chen, Shan-Chwen Chang.

Supervision: Wang-Huei Sheng, Hsin-Yun Sun, Shan-Chwen Chang.

Validation: Yu-Chung Chuang, Jen Jen Su.

Writing – original draft: Sung-Hsi Huang, Hsin-Yun Sun.

Writing – review & editing: Sung-Hsi Huang, Yu-Chung Chuang, Yi-Chien Lee, Chien-Ching Hung, Wang-Huei Sheng, Jen Jen Su, Hsin-Yun Sun, Yee-Chun Chen, Shan-Chwen Chang.

References
1. Pasquier E, Kunda J, De Beaudrap P, Loyse A, Temfack E, Molloy SF, et al. Long term mortality and disability in Cryptococcal Meningitis: a systematic literature review. Clin Infect Dis. 2017; 66: 1122–1132. https://doi.org/10.1093/cid/cix870 PMID: 29028957

2. Spec A, Olsen MA, Raval K, Powderly WG. Impact of Infectious Diseases Consultation on Mortality of Cryptococcal infection in Patients without HIV. Clin Infect Dis. 2017; 64: 558–564. https://doi.org/10.1093/cid/ciw786 PMID: 27927865

3. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011; 183: 96–128. https://doi.org/10.1164/rccm.2008-740ST PMID: 21193785

4. Rollesz MA, Huliesch KH, Rhein J, Nabela HW, Taseera K, Schutz C, et al. The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis. Clin Infect Dis. 2014; 59: 1607–1614. https://doi.org/10.1093/cid/ciu596 PMID: 25057102

5. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010; 50: 291–322. https://doi.org/10.1086/649858 PMID: 20047480
6. Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS ONE. 2013; 8: e60431. https://doi.org/10.1371/journal.pone.0060431 PMID: 2355970

7. Tseng H-K, Liu C-P, Ho M-W, Lu P-L, Lo H-J, Lin Y-H, et al. Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997–2010. PLoS ONE; 2013; 8: e61921. https://doi.org/10.1371/journal.pone.0061921 PMID: 23613973

8. Spec A, Raval K, Powderly WG. End-Stage Liver Disease Is a Strong Predictor of Early Mortality in Cryptococcosis. Open Forum Infect Dis 2015; 3: ofv197. https://doi.org/10.1093/ofid/ofv197 PMID: 26835475

9. Bratton EW, Hussein El N, Chastain CA, Lee MS, Poole C, Stümper T, et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS ONE. 2012; 7: e43582. https://doi.org/10.1371/journal.pone.0043582 PMID: 22937064

10. Chau TT, Mai NH, Phu NH, Nghia HD, Chuong LV, Sinh DX, et al. A prospective descriptive study of cryptococcal meningitis in Vietnam—high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis. 2010; 10: 199. https://doi.org/10.1186/1471-2334-10-199 PMID: 20618932

11. Ecevit IZ, Clancy CJ, Schmaffuss IM, Nguyen MH. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis. 2006; 42: 1443–1447. https://doi.org/10.1086/503570 PMID: 16619158

12. Liao C-H, Chi C-Y, Wang Y-J, Tseng S-W, Chou C-H, Ho C-M, et al. Different presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis. J Microbiol Immunol Infect. 2012; 45: 296–304. https://doi.org/10.1016/j.jmii.2011.12.005 PMID: 22608381

13. Shoham S, Cover C, Donegan N, Fulnecky E, Kumar P. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2005; 40: 477–479. https://doi.org/10.1086/427213 PMID: 15668874

14. Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Cryptococcal meningitis in non-HIV-infected patients. QJM. 2000; 93: 245–251. https://doi.org/10.1093/qjmed/93.4.245 PMID: 10787453

15. Jean S-S, Fang C-T, Shau W-Y, Chen YC, Chang SC, Hsueh P-R, et al. Cryptococcaemia: clinical features and prognostic factors. QJM. 2002; 95: 511–518. https://doi.org/10.1093/qjmed/93.8.511 PMID: 12145390

16. Sun HY, Hung C-C, Chang S-C. Management of cryptococcal meningitis with extremely high intracranial pressure in HIV-infected patients. Clin Infect Dis. 2004; 38: 1790–1792. https://doi.org/10.1086/421272 PMID: 15227631

17. Kung H-C, Huang P-Y, Chen W-T, Ko B-S, Chen Y-C, Chang S-C, et al. 2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan. J Microbiol Immunol Infect. 2018; 51: 1–17. https://doi.org/10.1016/j.jmii.2017.07.006 PMID: 28781150

18. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46: 1813–1821. https://doi.org/10.1086/588660 PMID: 18462102

19. Chen YC, Chang SC, Shih CC, Hung C-C, Luhbd KT, Pan YS, et al. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis 2000; 36: 175–183. PMID: 10729660

20. Hajian-Tilaki K. The choice of methods in determining the optimal cut-off value for quantitative diagnostic test evaluation. Stat Methods Med Res. 2017; 26: 96220821668038–10. https://doi.org/10.1177/0962280216680383 PMID: 28673124

21. Baddley JW, Perfect JR, Oster RA, Larsen RA, Pankey GA, Henderson H, et al. Pulmonary cryptococosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis. 2008; 27: 937–943. https://doi.org/10.1007/s10096-008-0529-z PMID: 18449582

22. Brouwer AE, Teparrukkul P, Pinpraphaporn S, Larsen RA, Chierakul W, Peacock S, et al. Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J Infect Dis. 2005; 192: 681–684. https://doi.org/10.1086/432073 PMID: 16028138

23. Osaka R, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, et al. Identifying Predictors of Central Nervous System Disease in Solid Organ Transplant Recipients With Cryptococcosis. Transplantation. 2010; 89: 69–74. https://doi.org/10.1097/TP.0b013e3181bcd4a1 PMID: 20061921
24. Wake RM, Britz E, Sriruttan C, Rukasha I, Omar T, Spencer DC, et al. High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients. Clin Infect Dis. 2018; 66: 686–692. https://doi.org/10.1093/cid/cix872 PMID: 29028998

25. To KK, Cheng VC, Tang BS, Fan YW, Yuen KY. False-negative cerebrospinal fluid cryptococcal antigen test due to small-colony variants of Cryptococcus neoformans meningitis in a patient with cystopleural shunt. Scand J Infect Dis. 2006; 38: 1110–1114. https://doi.org/10.1080/00365540600664118 PMID: 17148090

26. Currie BP, Freundlich LF, Soto MA, Casadevall A. False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J Clin Microbiol. 1993; 31: 2519–2522. PMID: 8408579

27. Sancesario G, Palmieri G, Viola G, Fontana C, Perfetti A, Anemona L, et al. Difficulty diagnosing chronic cryptococcal meningitis in idiopathic CD4+ lymphocytopenia. Neurol Sci. 2011; 32: 519–524. https://doi.org/10.1007/s10072-011-0496-5 PMID: 21384279

28. Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol. 2013; 190: 3959–3966. https://doi.org/10.4049/jimmunol.1202526 PMID: 23509356